Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
Highlights Third quarter revenue grew 11% year-over-year to $213 million, driven by Pharmacogenomics (34%) and Prenatal (10%) ...
Yahoo Finance17d
Myriad Genetics, Inc. (MYGN)
18, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision ... over-year to $212 million, driven by Prenatal (25%), Pharmacogenomics (22% ...
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
The company is scheduled to hold its third quarter 2024 earnings conference call after the market closes on Thursday November 7, 2024, and intends to provide additional information regarding its ...
Myriad Genetics plummets 20% as UnitedHealth changes GeneSight coverage
Myriad Genetics stock plunges after UnitedHealth Group announces they will no longer cover genetic tests for mental health ...
Morningstar4d
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
Morningstar brands and products Company Portfolio ...
The Globe and Mail3d
Myriad Genetics Comments on UnitedHealthcare’s Updated Medical Policy for Pharmacogenetic Testing
SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated ...
Stockhouse4d
Myriad Genetics Comments on UnitedHealthcare's Updated Medical Policy for Pharmacogenetic Testing
SALT LAKE CITY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, was informed on Friday, November 1, 2024, of an updated ...